Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Withdrawn 1Completed 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Glioma 4Glioblastoma 3Astrocytoma 3Recurrence 2Central Nervous System Neoplasms 2Neoplasms 1Gliosarcoma 1Brain Neoplasms 1

Interventions

Temozolomide 14Radiotherapy 14Carboplatin 7Irinotecan 6Everolimus 5Filgrastim 4Carmustine 4Surgical Procedures, Operative 3Radiation 3Paclitaxel 3Ifosfamide 3selpercatinib 2pembrolizumab 2Trastuzumab 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Methotrexate 2Imatinib Mesylate 2IL13-PE38 2Dasatinib 2Chemotherapy, Adjuvant 2Bevacizumab 2vitespin 1veliparib 1vatalanib 1transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38) 1tipifarnib 1terameprocol 1temsirolimus 1talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Central Nervous System Neoplasms × IL13-PE38 × Clear all
NCT00006268 2013-06-24

Immunotoxin Therapy in Treating Patients With Malignant Glioma

National Cancer Institute (NCI)

Phase 1/2 Completed
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00053040 2010-09-24

Immunotoxin Therapy in Treating Children With Recurrent Malignant Gliomas

Pediatric Brain Tumor Consortium

Phase 1/2 Withdrawn
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡